Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

JERSEY CITY, N.J., AUG. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

SCYNEXIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., MAY 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT PATIENT DOSING HAS RESUMED IN THE PHASE 3 MARIO STUDY, WHICH IS AN INNOVATIVE STUDY TO INVESTIGATE ORAL IBREXAFUNGERP AS A POTENTIAL STEP-DOWN ANTIFUNGAL THERAPY FOLLOWING IV ECHINOCANDIN FOR INVASIVE CANDIDIASIS, A LIFE-THREATENING INFECTION. THE STUDY HAD BEEN ON HOLD DUE TO CONCERNS ABOUT POTENTIAL CROSS-CONTAMINATION IN LIGHT OF DRAFT U.S. FOOD AND DRUG ADMINISTRATION (FDA) GUIDANCE REGARDING MANUFACTURING A NON-ANTIBIOTIC BETA-LACTAM (EZETIMIBE) AT THE SAME SITE AS IBREXAFUNGERP. THE STUDY HAS RESUMED FOLLOWING THE MANUFACTURE OF NEW CLINICAL SUPPLIES AT ANOTHER SITE AND THE LIFTING OF THE CLINICAL HOLD BY THE FDA. IF THE STUDY IS SUCCESSFUL AND APPROVAL FOR THIS INDICATION IS GRANTED BY THE FDA, IT WILL GIVE HEALTHCARE PROVIDERS THE OPPORTUNITY TO STEP-DOWN THEIR PATIENTS TO A NON-AZOLE ORAL THERAPY THAT RETAINS THE MECHANISM OF ACTION (GLUCAN SYNTHASE INHIBITION) OF THE IV-ONLY ECHINOCANDINS, WHICH ARE THE GOLD STANDARD FOR TREATMENT OFINVASIVE CANDIDAINFECTIONS. SCYNEXIS'S POSITION IS THAT THE DOSING OF THIS FIRST NEW PATIENT TRIGGERS A $10 MILLION PAYMENT FROM PARTNER GSK, WITH ANOTHER $20 MILLION PAYMENT TO BE TRIGGERED BY THE SIX-MONTH ANNIVERSARY OF DOSING.AS PREVIOUSLY DISCLOSED, THERE IS A DISAGREEMENT BETWEEN SCYNEXIS AND GSK REGARDING THE RESUMPTION OF THE MARIO STUDY AND GSK'S RESPONSIBILITY FOR PAYING THESE MILESTONES. SCYNEXIS IS WORKING TO RESOLVE THE DISAGREEMENT.

SCYNEXIS RESUMES PATIENT DOSING IN PHASE 3 MARIO STUDY

JERSEY CITY, N.J., MARCH 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024.

SCYNEXIS REPORTS FULL YEAR 2024 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., NOV. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024.

SCYNEXIS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., OCT. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED DAVID ANGULO, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2024 MAXIM HEALTHCARE VIRTUAL SUMMIT ON THURSDAY, OCTOBER 17, AT 11:30 A.M. ET.

SCYNEXIS TO PARTICIPATE IN THE 2024 MAXIM HEALTHCARE VIRTUAL SUMMIT

JERSEY CITY, N.J., OCT. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED UPCOMING PRESENTATIONS OF PRECLINICAL EFFICACY AND PHARMACOKINETIC DATA ON ITS SECOND-GENERATION FUNGERP CANDIDATE SCY-247 AT IDWEEK 2024 TAKING PLACE IN LOS ANGELES, CA FROM OCTOBER 16-19, 2024.

SCYNEXIS TO PRESENT PRECLINICAL DATA ON SECOND GENERATION FUNGERP SCY-247 AT IDWEEK 2024

JERSEY CITY, N.J., AUG. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED DAVID ANGULO, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL MAKE A CORPORATE PRESENTATION AS WELL AS HOST 1X1 MEETINGS AT THE H. C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON WEDNESDAY, SEPTEMBER 11 AT 10:00 A.M. ET.

SCYNEXIS TO PARTICIPATE IN H. C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE

JERSEY CITY, N.J., AUG. 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2024.

SCYNEXIS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., JULY 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT IT WILL RECEIVE A $10 MILLION DEVELOPMENT MILESTONE PAYMENT UNDER ITS EXCLUSIVE LICENSE AGREEMENT WITH GSK FOR IBREXAFUNGERP.

SCYNEXIS TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM GSK TRIGGERED BY DELIVERY OF COMPLETED FURI, CARES AND NATURE CLINICAL STUDY REPORTS

JERSEY CITY, N.J., MAY 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024.

SCYNEXIS, Inc.

SCYX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SCYNEXIS, Inc.

SCYX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SCYX